Serina Therapeutics completed enrollment for the first cohort of its Phase 1b trial testing SER-252, a sustained-release formulation of apomorphine for advanced Parkinson's disease. The approach addresses a fundamental principle in dopamine therapy: steady delivery may preserve neurological function better than the peaks and valleys created by current treatments.
Key Points
- Sustained dopamine delivery may reduce motor complications from dose fluctuations
- SER-252 uses proprietary formulation to replace problematic pump infusions
- First cohort safety review will determine dose escalation pathway
Longevity Analysis
Parkinson's progression reflects cumulative neurological wear—both from the disease itself and from treatment-induced fluctuations in dopamine signaling. The principle of steady-state delivery over pulsatile exposure carries implications beyond this single indication. How the nervous system receives chemical signals over time shapes its capacity to maintain coordinated function and resist age-related decline. A sustained-release approach may reduce the secondary damage that accompanies current therapies, preserving neurological reserve and functional capacity across the aging lifespan. This early-stage data represents a shift from replacing what is lost toward optimizing how what remains is delivered.
Original published by Longevity.Technology, by Kyle Umipig.